Related Experiment Video
Updated: Apr 28, 2026

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
Published on: February 2, 2024
Small Macrocycles As Highly Active Integrin α2β1 Antagonists
Nis Halland1, Horst Blum1, Christian Buning1
1Sanofi R&D , Industriepark Höchst Building G838, D-65926 Frankfurt am Main, Germany.
Researchers developed novel macrocyclic antagonists targeting the platelet collagen receptor α2β1. These potent compounds, with low nanomolar activity, show promising potential for further investigation.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Pharmacology
Background:
- Platelet collagen receptor α2β1 plays a crucial role in thrombosis and inflammation.
- Existing therapies targeting this receptor have limitations.
Purpose of the Study:
- To develop novel, potent, and selective antagonists of the platelet collagen receptor α2β1.
- To elucidate the structure-activity relationships and binding mode of these novel antagonists.
Main Methods:
- Design and synthesis of amino acid-derived macrocyclic compounds.
- In vitro biochemical assays to determine inhibitory activity (IC50 values) against integrin α2β1.
- X-ray crystallography to determine the three-dimensional structure of key compounds.
- Molecular docking studies to predict binding interactions within the α2β1 integrin.
Main Results:
- A series of 14-18-membered macrocycles were synthesized, showing high activity against integrin α2β1 with IC50s in the low nanomolar range.
- Macrocycle conformation was critical for activity, as revealed by X-ray crystallography.
- Docking studies provided insights into key binding features within the metal-ion-dependent adhesion site (MIDAS) of the β1 subunit.
- Macrocycle 38 emerged as a lead candidate for further preclinical development.
Conclusions:
- Novel macrocyclic compounds effectively antagonize the platelet collagen receptor α2β1.
- Structural insights guide the design of potent integrin α2β1 antagonists.
- Macrocycle 38 represents a promising candidate for further therapeutic development.
More Related Videos
09:45Modification and Functionalization of the Guanidine Group by Tailor-made Precursors
Published on: April 27, 2017
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
Intracellular Signaling Affects Focal Adhesions
Some...
Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...